Kinins are vasoactive and pro-inflammatory peptides whose biological effects are mediated by two GPCRs, named B 1 and B 2 receptors. While the B 2 receptor plays a protective role in the cardiovascular system via the activation of endothelial NOS, the B 1 receptor is associated with vascular inflammation, insulin resistance and diabetic complications. Because the B 1 receptor is a potent activator of the inducible form of NOS (iNOS), this study has addressed the role of iNOS in the deleterious effects of B 1 receptors in insulin resistance.
Introduction
Insulin resistance is considered as an early event in the development of type 2 diabetes mellitus in which mild vascular inflammation is a predictive factor. Vascular inflammation can be initiated by sustained hyperglycaemia-induced oxidative stress, which activates a series of receptors and transcriptional factors leading to increased levels of cellular adhesion molecules, macrophages and leukocyte infiltration in the vasculature and to endothelial dysfunction (He and King, 2004; de Vries et al., 2015; Gleissner, 2015) . Recently, we reported that the kinin B 1 receptor is involved in low-grade vascular inflammation and contributes to amplify and perpetuate the vascular oxidative stress in a rat model of insulin resistance induced by prolonged glucose feeding (Dias et al., 2010; Dias and Couture, 2012b; Couture et al., 2014) . In this model, oral treatment with the non-peptide B 1 receptor antagonist SSR240612 for 1 week reversed the enhanced expression of B 1 receptors, inducible nitric oxide synthase (iNOS) and other inflammatory key biomarkers (IL-1β, macrophage migration inhibitory factor, adhesion molecules and macrophages) in the vascular bed (Dias and Couture, 2012b) . The same prolonged blockade of B 1 receptors reversed hypertension, metabolic abnormalities (hyperglycaemia, hyperinsulinaemia and insulin resistance), the enhanced NADPH oxidase activity and the basal production of vascular superoxide anion (O 2 •¯) (Dias et al., 2010) .
Moreover, B 1 receptor activation was shown to enhance the production of O 2 •¯t hrough NADPH oxidase in the aorta of glucose-fed rats and in human epithelial cells (Dias et al., 2010; Talbot et al., 2011) . NADPH oxidase is known to produce the predominant source of reactive oxygen species in the vasculature that leads to diabetic complications and cardiovascular diseases (Cai et al., 2003; Taniyama and Griendling, 2003; Griendling and FitzGerald, 2003a; Griendling and FitzGerald, 2003b) . B 1 receptors can also generate high output and prolonged NO production from endothelial cells following the activation of iNOS via Gαi and the Src-dependent activation of the ERK/MAPK pathway (Kuhr et al., 2010; Brovkovych et al., 2011) . In an oxidative stress environment, the high concentration of NO can rapidly react with O 2
•¯t o form the highly reactive peroxynitrite (ONOO¯), which causes DNA damage (altering gene expression), inflammation and oxidative stress, notably lipid peroxidation (membranes) and nitration of proteins (enzymes, transporters and ion channels) (Johansen et al., 2005) . Importantly, the genetic deletion of iNOS prevents the development of insulin resistance in mice exposed to a high-fat diet (Perreault and Marette, 2001) and that of age-associated insulin resistance (Ropelle et al., 2013) . Mice lacking iNOS were protected against endotoxaemia-induced skeletal muscle insulin resistance and from lipid-induced hepatic insulin resistance through the iNOS/NO/ONOO¯pathway that causes tyrosine nitration (the covalent addition of NO 2 to the tyrosine residues) of insulin receptor substrate 1 (IRS-1) and thereby reduces its subsequent insulin-dependent tyrosine phosphorylation (Charbonneau and Marette, 2010; Pilon et al., 2010) . Hence, B 1 receptor-mediated iNOS activation and enhanced expression can be detrimental in cardiometabolic diseases as highlighted in a model of insulin resistance associated with hypertension (Dias and Couture, 2012b) . The latter hypothesis was directly tested in the present study by determining whether a 1 week pharmacological treatment with the selective inhibitor of iNOS 1400W (Garvey et al., 1997) could reproduce the beneficial effects of the B 1 receptor antagonist on insulin resistance, vascular and non-vascular inflammation and oxidative stress in the model of glucosefed rat. The impact of 1400W was also determined on the expression of B 1 receptors and carboxypeptidase M (CPM), a key enzyme involved in the generation of B 1 receptor ligands. This study highlights a partnership between B 1 receptors and iNOS in insulin resistance.
Methods

Animal care and treatments
Male Sprague-Dawley rats (24-30 days old), weighing 50-75 g, were purchased from Charles River Laboratories (Saint-Constant, QC, Canada). Rats were housed two per cage, under standard conditions (22.5°C and 42.5% humidity, on a 12 h/12 h light-dark cycle, using heated wood chip litter as bedding material) in a pathogen-free environment, and allowed free access to a standard chow diet (Teklad Global 18% Protein Rodent Diet) and to a drinking solution containing 10% D-glucose (querySigma-Aldrich, Oakville, ON, Canada) or tap water (control) for a period of 9 weeks.
A total of 24 rats were used in the experiments described here. During the last week (week 9), rats fed with glucose (G) or tap water (C) were randomly divided into four groups 
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of six rats: group 1 (G + 1400W), group 2 (G + Vehicle), group 3 (C + 1400W) and group 4 (C + Vehicle). 1400W (Focus Biomolecules, Plymouth Meeting, PA, USA), a selective inhibitor of iNOS (Garvey et al., 1997) , was given s.c. twice daily at 12 h intervals at the dose of 1 mg·kg À1 in a volume of 1 mL·kg À1 for 7 days. The vehicle (saline) was given in groups 2 and 4. Rats were subjected to several measurements, including systolic blood pressure, blood glucose and body weight during the treatment with 1400W. The dose of 1400W was selected on the basis of studies showing complete inhibition of endotoxin-induced vascular leakage in various rat tissues at the dose of 1 mg·kg À1 . When given i.v., rats tolerated a dose of 120 mg·kg À1 of 1400W for a 7 day period, and no apparent haemodynamic effect was seen up to 25 mg·kg À1 (Garvey et al., 1997) . All animal care and experimental procedures complied with the Use of Laboratory Animals and were approved by the Université de Montréal's Committee on Ethics in the Care and Use of Laboratory Animals (protocol 11-140) http:// www.cdea.umontreal.ca in accordance with the guiding principles as enunciated by the Canadian Council on Animal Care. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Experimental procedures
At the end of the ninth week, the blood was collected by cardiac puncture in overnight-fasted rats under isoflurane anesthesia. Blood samples were collected in tubes containing anticoagulant (Heparin; Sandoz, Boucherville, QC, Canada), and the plasma was separated by centrifugation at 600× g for 15 min at 4°C and stored at À20°C.
Three peripheral tissues (aorta, renal cortex and liver) were removed and kept frozen at À80°C. The thoracic aorta was the sentinel tissue to assess the anti-inflammatory and anti-oxidative effects of B 1 receptor blockade in our previous studies (Dias et al., 2010; Dias and Couture, 2012b) . The renal cortex and the liver were selected because diabetes induces glomerulosclerosis and nephropathy and the liver is the organ of glucose metabolism. Proteins, DNA and RNA of these organs were extracted to measure the expression of several inflammatory biomarkers [western blotting and quantitative RT-PCR (qRT-PCR)]. O 2
•¯w as measured in the thoracic aorta by a chemiluminescence technique using lucigenin.
Measurement of systolic blood pressure
Systolic blood pressure was measured by tail-cuff plethysmography (ADI Instruments Inc., Colorado, CO, USA) using a pad heated at 37°C, and registered with the ADI Instruments software (Lab Chart Pro7.Ink). Each measurement corresponds to the average of 5-7 blood pressure readings taken at 1-2 min intervals.
Biochemical analysis
Blood glucose concentration was determined with a glucometer (Accu-Chek Aviva; Roche Diagnostics, Laval, QC, Canada). Plasma insulin and leptin concentrations were determined by RIA using the double antibody/polyethylene glycol technique (rat insulin RIA kit and rat leptin RIA kit) from Millipore (St. Charles, MO, USA). The homeostasis model assessment (HOMA) index was used as an index of insulin resistance and calculated with the following formula:
[insulin (μU·mL À1 ) × glucose (mmol·L À1 )/22.5] (Matthews et al., 1985) .
Measurement of O 2
•T he production of O 2 •¯w as measured in the thoracic aorta according to the lucigenin-enhanced chemiluminescence method (Munzel et al., 1995) . The frozen aortic slices (2-5 mg) were pre-incubated in a Krebs-HEPES buffer (saturated with 95% O 2 and 5% CO 2 at room temperature) for 30 min and transferred to a glass scintillation vial containing 5 μM of lucigenin (200 μL in 2 mL Krebs-HEPES) to determine the O 2 •¯b asal level. The chemiluminescence was recorded every minute for 10 min in a dark room using a liquid scintillation counter (Wallac 1409, Turku, Finland).
To ascertain the contribution of NADPH oxidase in the basal production of O 2 •¯i n the aorta of control and glucose-fed rats treated or not with 1400W, diphenyleneiodonium (DPI, 10 μmol·L À1 ), a selective inhibitor of NADPH oxidase, was added to the medium 30 min prior to O 2 •¯m easurement in two additional slices of aortas in each group. The background was counted using a vial with no tissue solution. The final value expressed as cpm·mg À1 of dry weight tissue was calculated as follows: (tissue value À background value) ÷ tissue dry weight.
Western blot analysis
The western blot was performed according to a previous method (Dias et al., 2010; Pouliot et al., 2011) . Total proteins Table 1 List of primer pairs designed by Vector NTI software and used in qRT-PCR analysis Gene Sequence Position GenBank accession no. 5′  TCA ACT TTC GAT GGT AGT CGC CGT  3′  363-386  X01117   18S  Reverse  5′  TCC TTG GAT GTG GTA GCC GTT TCT  3′  470-447  X01117   B1R  Forward  5′  GCA GCG CTT AAC CAT AGC GGA AAT  3′  367-391  NM_030851   B1R  Reverse  5′  CCA GTT GAA ACG GTT CCC GAT GTT  3′  478-454  NM_030851   IL-1β  Forward  5′  TGT CAC TCA TTG TGG CTG TGG AGA  3′  247-270  NM_031512   IL-1β  Reverse  5′  TGG GAA CAT CAC ACA CTA GCA GGT  3′  411-388  NM_031513 were loaded (20-30 μg) in each well of 10% SDS-PAGE. After completion of the migration by electrophoresis, the proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Montreal, QC, Canada) at 100 V for 1 h. The membrane was then washed with PBS-Tween 20 and incubated for 1 h at room temperature in a blocking solution of 5% skimmed milk dissolved in PBS-Tween 20. The membrane was then cut in pieces according to the molecular weight of protein and incubated with specific primary antibodies in PBS-Tween 20 overnight at 4°C. Dynein and β-actin were used as standard proteins. After three sets of 10 min washing with PBS-Tween 20, the membrane was incubated for 1 h at room temperature in PBS-Tween 20 containing 5% skimmed milk with secondary antibodies. The membrane was washed three times (10 min per wash) with PBS-Tween 20 before being subjected to a reaction with a chemiluminescent detection reagent improved for the western blot (Super-Signal®; Thermo Scientific, Rockford, IL, USA). A quantitative analysis of proteins was provided by scanning densitometry using the MCID-M1 system (Imaging Research, St. Catharines, ON, Canada). Detection of bradykinin (BK) receptor proteins was made with selective anti-B 1 receptor and anti-B 2 receptor antibodies (1:1000) rose in rabbits (Biotechnology Research Institute, Montreal, QC, Canada) against a conserved amino acid sequence from B 1 and B 2 receptor proteins of mouse and rat. The epitopes used contained 15 amino acids localized in the C-terminal part of the B 1 receptor (VFAGRLLKTRVLGTL) and 15 amino acids localized in the second extracellular domain of the B 2 receptor (TIANNFDWVFGEVLC). Care was taken to avoid sequences with similarity to related mammalian proteins, including the opposite receptor. One negative control was run for each antibody using the pre-immune serum. Specificity of anti-B 1 receptor and anti-B 2 receptor antibodies was further determined using mouse kidney extracts from wild-type, B 1 and B 2 receptor knockout (KO) mice (Lin et al., 2010; Lacoste et al., 2013) .
18S Forward
The other primary antibodies were as follows: dynein (1:4000 mouse, SC-13524; Santa Cruz Biotechnology, CA, USA), β-actin (1:5000 mouse, SC-47778; Santa Cruz), IL-1β (1:500 rabbit, SC-7884; Santa Cruz), iNOS (NOS2) (1:1000 rabbit, SC-650; Santa Cruz), nitrotyrosine (1:1500 mouse, 1A6-05233; Millipores, Billerica, MA, USA) and carboxypeptidase M (1:500 rabbit, SC-98698; Santa Cruz). Secondary antibodies were horseradish peroxidase (HRP)-linked goat anti-rabbit SC-2004 and HRP-linked goat anti-mouse SC-2005 (Santa Cruz) used at dilution of 1:25000 (for B 1 and B 2 receptors), 1:5000 (for Dynein, β-actin, IL-1β, iNOS and CPM) and 1:3000 (nitrotyrosine).
qRT-PCR
After the animals had been killed the various organs were removed and around 10 mg of tissue (renal cortex, liver and thoracic aorta) were put in a RNAlater stabilization reagent (QIAGEN, Toronto, ON, Canada) and frozen at À56°C. Total RNA was extracted from the tissue using Qiazol according to the manufacturer's instructions. The single-stranded cDNA was synthesized according to the procedure in the manual supplied by Bio-Rad. qRT-PCR was performed in the SYBR Green Master Mix (QIAGEN) by adding 300 nM of each primer, and the signal was detected by Stratagene Mx3000p device (Thermo Fisher Scientific, Waltham, MA, USA) and using rat 18S as standard. The primer pairs were designed by Vector NTI software (Table 1) . The PCR conditions were as follows: 95°C for 15 min followed by 46 cycles at 94°C for 15 s, 60°C for 30 s and 72°C for 30 s. The cycle threshold value represents the number of cycles during which a fluorescent signal increases above the background noise. The relative quantification of gene expression was analysed by the method of 2-ΔΔCt (Livak and Schmittgen, 2001) .
Statistical analysis
Data are presented as mean ± SEM, and n represents the number of rats. Statistical analysis was performed using PrismTM version 5.0 (GraphPad Software Inc., La Jolla, CA, USA); data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Statistical significance was determined with Student's t-test for unpaired samples or with the oneway ANOVA followed by the Bonferroni test for multiple comparisons when F achieved P < 0.05 and there was no significant variance in homogeneity. Only the value of P ≤ 0.05 was considered to be statistically significant.
Results
Effect of 1400Won clinical parameters
Blood glucose level was increased by twofold (P < 0.05) in overnight-fasted glucose-fed rats compared with control rats, yet glycaemia was no longer significantly different from control values after 1 week treatment with 1400W (1 mg·kg À1 twice daily). Plasma insulin level was significantly increased by fourfold (P < 0.05) in glucose-fed rats and was blunted by the treatment with 1400W. The HOMA index of insulin resistance was also significantly enhanced (P < 0.05) in glucose-fed rats, yet this value was markedly reduced (P < 0.05) but not completely normalized by 1400W. In contrast, the same treatment with 1400W failed to affect glycaemia, insulinaemia and the HOMA index in control rats (Figure 1 ). The body weight was not significantly different between glucose-fed and control rats before (8 weeks) and after (9 weeks) treatment with 1400W (Table 2) . Nevertheless, the gain in body weight was significantly higher (P < 0.05) in glucose-fed rats after 9 weeks when compared with age-matched controls. The 1 week treatment with 1400W had no impact on the gain in body weight in control rats, but a significant loss in body weight (P < 0.05) was measured after treatment with 1400W in glucose-fed rats. As indicated in Table 2 , the leptin levels were significantly increased (P < 0.05) in the plasma of glucose-fed rats in comparison with control. The 1 week treatment with 1400W had no significant effect on plasma leptin levels in both control and glucose-fed rats, which remained significantly enhanced in the latter group. Systolic blood pressure was significantly enhanced (P < 0.05) in 9 week glucose-fed rats compared with control rats, and the high systolic blood pressure value was not significantly affected by the 1 week treatment with 1400W ( Table 2 ).
Effect of 1400Won oxidative stress
The impact of 1400W on oxidative stress was evaluated on the production of O 2
•¯a nd the expression of nitrotyrosine, a marker of ONOO¯. ONOO¯can modify tyrosine residue in various proteins to form nitrotyrosine, which could alter protein function and stability. As shown in Figure 2 , the basal production of O 2 •¯w as significantly enhanced (P < 0.05) in the aorta of glucose-fed rats when compared with control rats. The 1 week treatment with 1400W increased significantly (P < 0.05) the basal production of O 2 •¯i n control rats but failed to affect significantly the increased basal production of O 2 •¯i n glucose-fed rats. The basal production of O 2 •¯i n the aorta of control and glucose-fed rats treated or not with 1400W was completely abolished when the tissue was treated for 30 min with DPI (10 μmol·L À1 ), confirming the involvement of NADPH oxidase in the production of O 2 •¯( data not shown).
In control renal cortex, nitrotyrosine epitopes were detected in proteins with molecular masses of about 55 and 70-85 kDa. In glucose renal cortex, the intensity of those original nitrotyrosine epitopes increased, and other nitrosylated proteins occurred at about 50 and 60 kDa. Treatment with 1400W significantly reduced the intensity of nitrotyrosine-containing proteins in glucose renal cortex to levels not significantly different from control. Likewise, nitrosylated proteins with molecular masses of about 70-80 and 90-95 kDa were detected in control aorta, and their intensity was higher in glucose aorta, which also displayed additional nitrosylated proteins at molecular masses of 110 and 150 kDa. Treatment with 1400W significantly reduced the expression of these nitrosylated proteins in both control and glucose aortas (Figure 3 ).
Effect of 1400Won B 1 receptors and carboxypeptidase M
Levels of B 1 receptor mRNA and protein were markedly and significantly enhanced in the three tissues (renal cortex, aorta and the liver) of glucose-fed rats (Figure 4) . The 1 week treatment with 1400W reduced B 1 receptor expression, particularly at the mRNA level in renal cortex, aorta and liver. While B 1 receptor mRNA levels were completely abolished by 1400W, B 1 receptor protein levels remained significantly increased when compared with control values in aorta and liver. The lack of correlation between B 1 receptor gene and protein expression is unexplained but may indicate that the B 1 receptor remains expressed at the cell membrane beyond the inhibition of its synthesis by 1400W. The treatment with 1400W failed, however, to affect significantly B 1 receptor mRNA and protein expression in the three tissues in control rats (Figure 4 ). Protein expression of CPM was also significantly increased (P < 0.05) in the renal cortex, aorta and liver of glucose-fed rats. The 1 week treatment with 1400W abolished the overexpression of CPM in the renal cortex and aorta of glucose-fed rats but failed to affect that in the liver. 1400W had no significant impact in the three control tissues ( Figure 5 ).
Effect of 1400Won iNOS and IL-1β
Protein expression of iNOS was found to be significantly increased (P < 0.05) in the renal cortex, aorta and liver of glucose-fed rats. The 1 week treatment with 1400W abolished the enhanced expression of iNOS in the two former tissues but had no significant effect on iNOS in the liver of glucosefed rats. Treatment with 1400W had no significant impact in the three control tissues ( Figure 6 ). In glucose-fed rats, the expression of IL-1β was also significantly enhanced at mRNA and protein levels in the renal cortex, aorta and liver (Figure 7) . The 1 week treatment with 1400W abolished the increased mRNA expression in the three tissues in glucosefed rats without affecting basal expression of IL-1β in control rats. The impact of 1400W on IL-1β protein expression was less striking. For instance, it had a reducing effect in the renal cortex and aorta but not in the liver where IL-1β protein expression remained significantly elevated compared with its control (Figure 7 ).
Effect of 1400Won B 2 receptor expression
Protein expression of B 2 receptors was not affected in the renal cortex and aorta but was significantly increased (P < 0.05) in the liver of glucose-fed rats. Although B 2 receptor expression was not altered by the 1 week treatment with 1400W in the aorta, it was significantly decreased in the control and glucose renal cortex (P < 0.05). In contrast, treatment with 1400W increased the expression of B 2 receptors in the control liver (P < 0.05) to values measured in glucose-fed rats, showing an absence of inhibition of the upregulated B 2 receptors in the liver of glucose-fed rats (Figure 8 ).
Discussion
In this study, we demonstrated that 1 week treatment with a selective inhibitor of iNOS (1400W) improved insulin resistance, hyperglycaemia, hyperinsulinaemia and reversed body weight gain without affecting hypertension and hyperleptinaemia in glucose-fed rats. The beneficial effects of 1400W on those metabolic abnormalities were associated with a correction of ONOO¯formation and of upregulated biomarkers of inflammation (B 1 receptor, iNOS and IL-1β) in peripheral tissues. In addition, the up-regulation of CPM (kininase I), a key enzyme involved in the biotransformation of BK and Lys-BK into their active C-terminal metabolites (des-Arg 9 -BK and Lys-des-Arg 9 -BK), the preferred endogenous agonists at B 1 receptors (Regoli and Gobeil, 2015) , was reversed by 1400W in glucose-fed rats. These findings strongly suggest that the deleterious effects of iNOS are linked to B 1 receptor activation. The production of ONOO¯upon iNOS activation by B 1 receptors may contribute to insulin resistance by blocking tyrosine phosphorylation of IRS-1 subsequently to tyrosine nitration (Pilon et al., 2010) . Because the B 1 receptor is virtually absent in physiological situations, this study is the first to suggest that the reactive nitrogen derivative ONOO¯is more important than O 2 •¯i n hyperglycaemia-induced up-regulation of B 1 receptors and may act as a positive feedback mechanism (Figure 9 ).
Impact of 1400Won peripheral cardiometabolic targets and oxidative stress
Levels of O 2 •¯, a marker of oxidative stress, were significantly enhanced in the aorta of glucose-fed rats and remained unaffected by 1400W. In this model of insulin resistance, basal production of O 2 •¯d erived mainly from NADPH oxidase (sensitive to DPI), which was also found to be activated by a B 1 receptor agonist to raise the formation of O 2
•¯i n the aorta of glucose-fed rats (Dias et al., 2010) . Thus, the failure of 1400W to prevent the enhanced generation of O 2
•¯i s logical. Indeed, the inhibition of iNOS prevents the formation of NO and thereby is likely to compromise its binding with O 2 •¯t o form ONOO¯. This can afford an explanation for the inhibition of ONOO¯in aorta and renal cortex with the consequent accumulation of O 2 •¯i n the tissue as observed in control aorta under iNOS inhibition.
Previous studies have reported that the B 1 receptor can be upregulated by its own agonist in human fibroblasts (Schanstra et al., 1998) and in vivo on blood vessels as the blockade of B 1 receptors with SSR240612 reversed the upregulation of B 1 receptors in glucose-fed rats (Dias et al., 2010; Dias and Couture, 2012a,b) . The enhanced formation of B 1 receptor agonists (des-Arg 9 -BK and Lys-des-Arg 9 -BK) following the overexpressed CPM appears therefore a feasible mechanism for B 1 receptor up-regulation. By reversing the up-regulation of CPM with 1400W, the over activation of the B 1 receptor by its endogenous agonists is suppressed, leading to a normalisation of B 1 receptor expression at mRNA and protein levels. By this mechanism, iNOS inhibition targets both B 1 receptor ligands and B 1 receptor expression.
In a recent study, we have shown that a 1 week treatment with the B 1 receptor antagonist SSR240612 reversed body weight gain without affecting hyperleptinaemia in glucose-fed rats (Dias and Couture, 2012a) , which reinforces a role for the B 1 receptor in obesity that could be mediated by iNOS as the up-regulation of iNOS in retroperitoneal adipose tissue was also reversed by SSR240612 in glucose-fed rats. Obesity is associated with increased iNOS expression in insulin-sensitive tissues in rodents and humans, and inhibition of iNOS ameliorates obesityinduced insulin resistance (Kaneki et al., 2007) . However, a primary role for leptin in body weight gain associated with B 1 receptors and iNOS is not supported by our studies using either SSR240612 (Dias and Couture, 2012a) or 1400W. Thus, the B 1 receptor contributes to insulin resistance through a mechanism that is iNOS-dependent and leptin-independent.
Although 1400W prevented insulin resistance, it failed to affect the associated hypertension in chronic glucose-fed rats. This may indicate that hypertension is not related to peripheral iNOS or to the overproduction of vascular oxidative stress (O 2 •ā nd ONOO¯) or to peripheral B 1 receptor expression and activation. Indeed, it was found that only non-peptide antagonists of B 1 receptors that could pass the blood-brain barrier to inhibit B 1 receptors in the central nervous system can reverse high systolic blood pressure in glucose-fed rats, spontaneously hypertensive rats and angiotensin II-induced hypertension (Lungu et al., 2007; De Brito Gariepy et al., 2010; Dias et al., 2010) .
Figure 9
Schematic diagram of the signalling pathway activated by B 1 receptor agonists leading to the formation of ONOO¯upon post-translational activation of iNOS and NADPH oxidase. Activation of the B 1 receptor through Gαi and βγ-dependent activation of Src, Ras, Raf and MEK leads to ERK-dependent phosphorylation of iNOS on Ser 745 that causes high NO output (Brovkovych et al., 2011) . Interestingly, increased expression and activity of iNOS were reported in superior mesenteric arteries from 12 to 14 week streptozotocin-induced diabetic rats (Bardell and MacLeod, 2001) . In this model of type 1 diabetes, rats are not hypertensive and display a phenotype of cardiovascular depression (depressed mean arterial blood pressure and heart rate resistant to 1400W) associated with enhanced expression of iNOS and nitrotyrosine in cardiovascular tissues and with endothelial dysfunction (Nagareddy et al., 2005) . Consistently, iNOS knockout mice are resistant to endothelial dysfunction during diabetes (Gunnett et al., 2003) . Hence, iNOS induction in cardiovascular tissues may not contribute directly to high systemic blood pressure in insulin resistance and to low systemic blood pressure in type 1 diabetes despite impairment of endothelial function.
Impact of 1400Won inflammatory markers
The suppression of the enhanced expression of B 1 receptors and IL-1β at mRNA levels by 1400W occurred in the three tissues studied (aorta, renal cortex and the liver) of chronic glucose-fed rats, suggesting that the inflammatory process is not restricted to the vasculature. Nevertheless, protein expression of the B 1 receptor, CPM, IL-1β and iNOS was more resistant to 1400W in the liver, suggesting that the enhanced expression of these markers in the liver may be differently regulated at transcriptional and post-transcriptional levels in this model of insulin resistance. Also, B 2 receptor protein expression was increased in the liver but not in the two other tissues in glucose-fed rats, and again, it was resistant to iNOS blockade. In agreement with this study, 1 week blockade of B 1 receptors with SSR240612 reversed the overexpression of iNOS, B 1 receptors and IL-1β in the aorta of glucose-fed rats (Dias et al., 2010; Dias and Couture, 2012b) . Hence, in addition to being involved in the ERK/MAPK activation of iNOS, the B 1 receptor may control the expression of iNOS through ONOO¯formation in blood vessel. In this context, it is worth noting that B 1 receptor-induced activation of iNOS plays a primary role in lethal thrombosis in a rat model of septic shock in diabetes (Tidjane et al., 2015) .
Conclusion
Pharmacological blockade of iNOS provides the same beneficial effects as B 1 receptor blockade in insulin resistance and peripheral inflammation in chronic glucose-fed rats. Inhibition of ONOO¯formation by the selective iNOS blocker 1400W appears to be a possible downstream target mechanism that prevents the positive feedback up-regulation and activation of the pro-inflammatory B 1 receptor by endogenous ligands under the control of carboxypeptidase M. These findings have clinical relevance in the treatment of insulin resistance and type 2 diabetes where iNOS and the B 1 receptor represent promising therapeutic targets.
